GlassScriptPhysician profile
Vidyamohan Balu
NPI 1265815880
$2,122.80
in general payments reported to CMS, 2019-2025
29 companies · $341 in 2025
The $341 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134 · 2020: $126 · 2021: $236 · 2022: $222 · 2023: $410 · 2024: $654 · 2025: $341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,350 · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,349.98 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $626.58 | 2022-2025 | Qulipta, Linzess, Ubrelvy |
| Lilly USA, LLC | $242.58 | 2019-2025 | Mounjaro, Emgality, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.82 | 2021-2024 | Spiriva Respimat, Stiolto Respimat |
| Astellas Pharma US INC | $110.69 | 2021-2024 | Veozah |
| Janssen Pharmaceuticals, INC | $101.86 | 2020-2022 | |
| Glaxosmithkline, LLC. | $93.49 | 2019-2023 | Nucala |
| Novo Nordisk INC | $88.18 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Shield Therapeutics INC | $83.15 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $79.31 | 2022-2025 | Airsupra, Farxiga |
| Novartis Pharmaceuticals Corporation | $61.76 | 2021-2023 | |
| Harmony Biosciences LLC | $54.99 | 2024 | |
| Pfizer INC. | $54.76 | 2020-2024 | |
| Mylan Specialty L.P. | $50.97 | 2021-2022 | |
| Genzyme Corporation | $39.06 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $37.85 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $26.00 | 2025 | Ibsrela |
| Indivior INC. | $25.75 | 2019-2020 | |
| Grifols USA, LLC | $25.19 | 2024 | Prolastin-C Liquid |
| Abbott Laboratories | $24.11 | 2025 | Freestyle Libre 3 |
| Viatris Specialty LLC | $22.48 | 2025 | Yupelri |
| Baxter Healthcare | $22.44 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Allergan, INC. | $20.16 | 2020 | |
| Idorsia Pharmaceuticals US INC | $19.84 | 2023 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $19.50 | 2024 | Rexulti |
| Sunovion Pharmaceuticals INC. | $17.96 | 2022 | |
| Electromed, INC. | $16.40 | 2022 | |
| Alkermes, INC. | $15.93 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.84 | 2025 | Caplyta |
| Scilex Pharmaceuticals INC. | $15.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vidyamohan Balu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.